AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02993887 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness
Description: The mindfulness intervention will include the use of an app daily via Stop, Think, Breathe.
Study NCT02993887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The mindfulness intervention will include the use of an app daily via Stop, Think, Breathe.
Study NCT01859793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: 100 mg pill, administered once/day orally
Study NCT01859793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo in appearance given once/day orally
Study NCT04557098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered SC.
Study NCT02143037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prize contingency management for attending treatment
Study NCT02143037 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Study NCT02143037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: usual care
Study NCT03116464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemental Health Family Intervention
Description: Approximately 12-16 session family intervention that will include the following specific strategies, the implementation of which will be tailored by clinicians to the specific interpersonal deficits identified in an assessment: (1) psychoeducation on dementia, (2) communication and problem solving skills, (3) safety building skills, (4) relationship satisfaction enhancement skills, (5) meaning making (i.e. collaboratively identifying the personal significance of events), (6) identification of core patterns from dyad relationship history, (7) techniques to shift emotional responses, (8) techniques to increase emotional attunement, and (9) techniques to increase attunement to care-recipient needs
Study NCT03988582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T-cells
Description: During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period.
Study NCT04323982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new surgical procedure
Description: （ACCC + I / A + PCCC + TA+ A-vit) or （ACCC + I / A + PCCC + IOL + TA + A-vit）
Study NCT04323982 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional surgical procedure
Description: （ACCC + I / A + PCCC + A-vit) or （ACCC + I / A + PCCC + IOL + A-vit）
Study NCT00735111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Karnofsky Performance Status Score
Description: Karnofsky Performance Status scores will be independently completed by both the patient and their health-care provider at each routine clinic visit.
Study NCT01977261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closing-wedge HTO
Description: Closing-wedge high tibial osteotomy fixated with two staples
Study NCT00186914 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Marrow stromal cell infusion
Description: This is a pilot study of infusions of ex vivo expanded, gene marked donor bone marrow stromal cells following allogeneic bone marrow transplantation. The study is a within patient dose escalation safety evaluation. It is believed that this patient population may benefit from these donor stromal cell infusions.~As the stromal cells will be obtained from the original stem cell donor, no conditioning is required.~Patients will receive two infusions of mesenchymal cells (MSC) approximately 14 to 21 days apart unless there is unacceptable toxicity after the first infusion. The first dose of cells to be given will be 1x10\^6 MSC/kg and the second dose of cells will be 5x10\^6 MSC/kg. The patients will be followed for approximately 28 days following the second infusion for any toxicity. Only after all six patients have safely completed both infusions will we consider 5 x 10\^6 MSC/kg a safe dose of allogeneic mesenchymal stem cells for infusion.
Study NCT02127047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Study NCT02127047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT01773512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: All patients will be using rosuvastatin 40 mg
Study NCT00192296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 0.3 mg/kg
Description: MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
Study NCT04661241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automatic DRT/VIM target-recognition method using MR-SISET and ML approaches
Description: The proposed sequence (\<15 minutes) will be added as a supplementary sequence only for the preoperative imaging for subjects who agree to participate: a 3D multi-echo GRE sequence will be performed during a preoperative MR imaging, using the following parameters: field of view = 220x170x75 mm3, matrix = 176x136x60, 1.25-mm isotropic resolution, flip angle = 22 degrees, TR = 92 ms, 20 TEs = 1.90 - 45.98 ms with echo spacing of 2.32 ms, bandwidth = 840 Hz/pixel.
Study NCT04661241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine clinical MRI protocol
Description: MRI will be performed using 3T scanner (Skyra, Siemens, Erlangen, Germany). All patients will undergo preoperative MRI of the brain including routine clinical MRI protocol (T1-/T2-weighted and diffusion imaging) under general anesthesia to reduce movement artifacts.
Study NCT00192296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 1 mg/kg
Description: MEDI-528 (1 mg/kg) administered as a single, IV dose
Study NCT03790878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Breathing
Description: Training in a mindful breathing skill that reduces emotional distress
Study NCT03790878 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habituation
Description: An exposure procedure that reduces emotional distress through habituation
Study NCT03790878 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No emotion regulation intervention, placebo
Study NCT03353155 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study NCT03353155 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CareHub
Study NCT03644784 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standardized protocol for assessing aortic regurgitation using videodensitometry
Description: Standardized protocol for assessing aortic regurgitation using videodensitometry
Study NCT00192296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 3 mg/kg
Description: MEDI-528 (3 mg/kg) administered as a single, IV dose
Study NCT00192296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 9 mg/kg
Description: MEDI-528 (9 mg/kg) administered as a single, IV dose
Study NCT03880279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAC01-CD19
Description: Dose-escalating cohorts plus expansion groups
Study NCT04437693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: The treatment group that will receive Hydroxychloroquine (HCQ) 400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks
Study NCT01999075 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung Volume Recruitment (LVR)
Description: LVR will be used twice per day
Study NCT01999075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Treatment
Description: This may include: a. Physiotherapy, consisting of percussion, active cycle of breathing and/or postural drainage; b. Nutritional support, consisting of oral or tube-fed dietary supplements; c. Antibiotics (oral or intravenous), if there is evidence of respiratory infection; d. Non-invasive positive pressure ventilation, if there is evidence of nocturnal hypoventilation or sleep-disordered breathing; e. Systemic steroids
Study NCT01999075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: This may include: a. Physiotherapy, consisting of percussion, active cycle of breathing and/or postural drainage; b. Nutritional support, consisting of oral or tube-fed dietary supplements; c. Antibiotics (oral or intravenous), if there is evidence of respiratory infection; d. Non-invasive positive pressure ventilation, if there is evidence of nocturnal hypoventilation or sleep-disordered breathing; e. Systemic steroids
Study NCT03842189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M281
Description: Participants will receive once weekly intravenous (IV) infusions of M281
Study NCT02681328 — intervention group
Intervention type: OTHER
Intervention: Afirma GEC
Description: Afirma GEC molecular test on collected thyroid tissue
Study NCT01478672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Health Coaching and Life-long Monitoring
Description: Participants receive tablet PCs with software that collects and transmit diagnostic measurements. Measurements are performed by the participants following indications of the health coaching team. Equipment used by all participants: • blood pressure meter, • pedometer • pulse watch• 2-channel electrocardiograph. Measured values are entered manually by the participants, unrealistic values are refused and values are provided with a time-stamp. Measurements is reviewed in a graphical display. Measured values are accessed by the health coaching team that develops an individualized measurement and medication scheme. Reminders are provided by the software and can be exported to personal calendars or mobile phones. Secure authentication of users is be provided
Study NCT02681328 — intervention group
Intervention type: OTHER
Intervention: ThyroSeq v.2
Description: ThyroSeq v.2 molecular test on collected thyroid tissue
Study NCT02681328 — intervention group
Intervention type: OTHER
Intervention: Afirma GSC
Description: Afirma GSC molecular test on collected thyroid tissue
Study NCT02681328 — intervention group
Intervention type: OTHER
Intervention: ThyroSeq v.3
Description: ThyroSeq v.3 molecular test on collected thyroid tissue
Study NCT00531713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triiodothyronine
Description: 50 microgram of the usual T4 is withdrawn and the patients is given 20 microgram of T3
Study NCT01901770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive HPV vaccination educational materials
Study NCT01901770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive influenza vaccination educational materials
Study NCT03156634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PALS
Description: PALS is a web based patient education system that uses text and audiovisual formats to deliver patient education materials.
Study NCT03156634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WebMD
Description: WebMD is an internet based health information source.
Study NCT01899456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter-based renal denervation
Study NCT02601534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zero-time Exercise
Description: a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve physical activity habit.
Study NCT02601534 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Eating
Description: a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve dietary habit.
Study NCT00542438 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Recall
Description: Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
Study NCT00542438 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Environmental Assessments
Description: Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
Study NCT04226547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)
Description: Implantation of an Amplatzer Amulet left atrial appendage occluder
Study NCT04226547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Vitamin K Oral Antagonists
Description: Initiation or continuation of a NOAC drug
Study NCT04455308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological sample collection
Description: 10mL blood sample
Study NCT04455308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biological sample collection
Description: 10mL blood sample
Study NCT01686880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirsphere trans-arterial radioembolization
Description: Patients will receive Sirsphere trans-arterial radioembolization before surgery
Study NCT04461743 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention, regular therapy
Study NCT04437693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine
Description: The treatment group that will receive Hydroxychloroquine (HCQ) 400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks
Study NCT00240006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shared Solutions® plus MS Center v. Shared Solutions®
Description: Copaxone
Study NCT00446069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulphate
Description: Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
Study NCT00446069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulphate
Description: Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
Study NCT01910987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib (optimized retreatment)
Description: Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1, 4, 8 and 11, every 21 days of cycle 1 and 2; injection on Days 1, 8, 15, 22, every 35 days for cycles 3 to 6; followed by injections on Days 1, 8, 15, 22 every 35 days (Group A1) or injections every other week (Group A2). Treatment will be stopped at confirmed disease progression
Study NCT02247336 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family health history platform (MeTree)
Description: Participants will enter their family health history information into a family health history platform, patients and providers will receive a decision support document and pedigree
Study NCT02247336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family health history platform (MeTree)
Description: Participants will enter their family health history information into a family health history platform, patients and providers will receive a decision support document and pedigree
Study NCT04642820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: Participants will be given 20 mg of Methamphetamine.
Study NCT04642820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo oral tablet
Description: Participants will be given a placebo capsule that will only contain lactose.
Study NCT01910987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone (optimized retreatment)
Description: Type= exact number, unit = mg, number = 20, form = tablet, route = oral, intake on Days 1, 2, 4, 5, 8, 9, 11 and 12, every 21 days of cycle 1 and 2; intake on Days 1, 2, 8, 9, 15, 16, 22 and 23 every 35 days for cycles 3 to 6
Study NCT01910987 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bortezomib (standard retreatment)
Description: Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1,4,8,11, every 21 days for cycles 1 to 8 or until confirmed disease progression
Study NCT01910987 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone (standard retreatment)
Description: Type = exact number, unit = mg, number = 20, form = tablet, route= oral, intake on Days 1, 2, 4, 5, 8, 9, 11, 12, every 21 days for cycles 1 to 8 or until confirmed disease progression
Study NCT00595738 — intervention group
Intervention type: OTHER
Intervention: Standard of care therapy for severe decompensated heart failure
Description: Standard of care therapy for severe decompensated heart failure
Study NCT03834766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMPH ER Tab 5, 10, 15 and 20 mg
Description: Amphetamine
Study NCT03834766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg
Description: Placebo
Study NCT02655510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-652
Description: Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg.
Study NCT04599348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HRG 80 Red Ginseng
Description: A unique form of ginseng with the high level of active ginseng components similar to those found in the wild ginseng used in earlier studies.
Study NCT04455191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thawing Embryos in Advance
Description: Thaw Embryos one day in Advance
Study NCT04455191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thawing Embryos on the Day of Transfer
Description: Thaw Embryos on the morning of transfer day.
Study NCT04778462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave and conventional treament
Description: Extracorporeal shock wave for 700 impulses of 0.056 mJ/mm at a frequency of 10 Hz to the taut band and 300 impulses surrounding the taut band will be applied as low energy 2 sessions per week for 2 weeks The will be used as a radial type of shock wave therapy.~Strengthening, stretching exercises and ischemic compression:~1. Isometric neck extensor exercise:~2. Isometric neck flexor exercise:~3. Isometric neck side bending muscle exercise:~Stretching exercise:~Passive stretching for the neck extensor muscles:~Passive stretching of the neck side-bending muscles:~Ischemic compression
Study NCT04778462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high pain threshold ultrasound and conventional treatment for myofascial pain syndrome trigger points
Description: will be applied in continuous mode, with the probe placed directly on the TrP and held motionless. To elicit threshold pain, the US probe will be kept static on the TrP. Intensity gradually will be increased to the level of maximum pain the patient could bear. It will be kept at that level for 3 to 4 seconds, then will be reduced to the half-intensity level for another 15 seconds. This procedure was repeated 3 times.the intensity of US will be dependent on the patient's level of pain. intensity will be applied in the range of 0.5 to 2.0 Watt per/cm2. Patients continually report their pain level and its localization and nature High-power pain threshold US will be applied 4 times, with a 3-day interval 2 sessions per week for 2 weeks .~1)Isometric neck extensor exercise2)Isometric neck flexor exercise3)Isometric neck side bending muscle exercise,Stretching exercise:Passive stretching for the neck extensor muscles ,stretching of the neck side-bending muscles,Ischemic compression
Study NCT04778462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional treatment for myofascial pain trigger point
Description: Strengthening, stretching exercises and ischemic compression:~1. Isometric neck extensor exercise:~2. Isometric neck flexor exercise:~3. Isometric neck side bending muscle exercise:~Stretching exercise:~Passive stretching for the neck extensor muscles:~Passive stretching of the neck side-bending muscles:~Ischemic compression
Study NCT04275921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI analysis using TWIST and HASTE
Study NCT04275921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 4D MRI
Description: 4D MRI alongside 4D CT in lung cancer
Study NCT01243996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Treatment with high (20-10-10 mg/kg/day)or standard dose(10-5-5 mg/kg/day) ibuprofen